Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02263079 · ClinicalTrials.gov registry record · Phase 3
A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 62
- Enrollment target
NCT02263079 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 62 participants.
The verdict
NCT02263079, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 62 participants
- Enrollment target
Study Summary
This randomized, controlled, parallel group, open-label multicenter study will evaluate the efficacy and safety of a combination of pegylated interferon alfa-2A (Pegasys) plus lamivudine or entecavir compared with an untreated control group in participants with HBeAg positive CHB in the immune tolerant phase. NOTE: STUDY RECRUITMENT HAS BEEN TERMINATED
Interventions
- DRUG Lamivudine
- DRUG Entecavir
- DRUG Pegylated Interferon Alfa-2A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2014-06-16 |
| Est. Completion | 2020-01-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02263079
The ClinicalTrials.gov registry entry for NCT02263079 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lamivudine is the first listed.
NCT02263079 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02263079 about?
NCT02263079 is a clinical study titled "A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase". This randomized, controlled, parallel group, open-label multicenter study will evaluate the efficacy and safety of a combination of pegylated interferon alfa-2A (Pegasys) plus lamivudine or entecavir compared with an untreated control group in participants with HBeAg positive CHB in the immune toler...
What is the current status of trial NCT02263079?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 62 participants. The study started on 2014-06-16. Estimated completion is 2020-01-29.
What interventions are being tested in trial NCT02263079?
The interventions under investigation include: Lamivudine (DRUG), Entecavir (DRUG), Pegylated Interferon Alfa-2A (DRUG).
Who is sponsoring clinical trial NCT02263079?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.